SMOORE
13.10.2021 07:52:07 CEST | Business Wire | Press release
SMOORE, a global leader in offering vaping technology solutions, today announced that its flagship tech brand, FEELM, has received a gold award in the product design category of 2021 MUSE Design Awards for its ultra-slim disposable vape with ceramic coil, TA15. Moreover, FEELM is the only brand winning 2021 MUSE Design Award in the atomization field. The MUSE Design Awards is an international competition for designers whose craftsmanship leads to paradigm shifts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012006272/en/
As the world’s first disposable ultra-slim pod product equipped with ceramic coil, TA 15 marks the opening of a new ceramic era of disposable vapes. FEELM atomization coil inside TA 15 guarantees low power consumption, stronger vapor, stable and popping-free vaping experience. Despite its ultra-slim body, TA15 is long-lasting for over 300 puffs.
Moreover, TA15 adopts an anti-condensation structure to control the dynamic condition of e-liquid, lowering the leakage rate to the greatest extend and offering premium user experience.
The slightly arc surface wraps the inner structure compactly forming a 7.5 mm thinnest body. The vertically textured surface makes it comfortable to hold and reduces remains of fingerprints. The raised part of TA 15 prevents the mouthpiece from contact with desk for hygiene and features a concealed air inlet.
Meanwhile, the highlighted “pixel block” is actually a metal sticker, whose color is changed with flavors and support customization.
By virtue of unique design and innovation technology, this product has effectively solved the industry’s pain point of leakage without a silicone plug. Thanks to breakthrough in materials and structural science, there’s no burnt taste, but with more delicate vapor and purer taste, thus delivering an extraordinary vaping experience.
“I always put users first, and attempt to deeply understand and explore their potential needs. Driven by design thinking, we combine practicability and minimalism, highlighting the performance of our ceramic coil while making other parts as thin as possible.” said Qing Ling, ID Designer of TA15.
Since its global launch in 2016, FEELM has a significant impact on the research and manufacturing of closed vaping products and changed the global vaping industry landscape, ushering into a new era of ceramic coil.
The MUSE Design Awards is a part of the MUSE Awards Program, which was created by the International Awards Associate (IAA) in 2015. IAA’s inception was based on a mission to honor, promote and encourage creativity by providing a new standard of excellence for evaluating media design production and distribution. IAA’s mission has largely shaped MUSE Design Awards' goals.
For more information, please visit https://design.museaward.com/winner-info.php?id=6819
About FEELM:
FEELM is a flagship atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high-quality atomization devices driven by FEELM coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom